all the latest information
therapeutic class and intervention. Listed below are recently updated therapeutic classes.
GvHD prophylaxis with PTCy allows for rapid hematopoietic reconstitution and improved survival in transplanted patients with severe aplastic anemia
A summary of the study conducted by DeZern and...
A retrospective analysis of allogeneic stem cell transplantation for peripheral T-cell lymphoma
Anne-Claire Mamez and colleagues examined the outcomes of allo-HSCT in patients with non-primary...
Donor macrophages promote human acute GvHD in allogeneic BMT
A study published by Laura Jardine and colleagues in the Journal of Clinical Investigation examined acute GvHD skin lesions, to identify...
Is arsenic trioxide effective in treating aGvHD? Results from an in vitro study
Xiao Liu and colleagues conducted a preclinical study to investigate the role of macrophage polarization in aGvHD and...
Submission of biologics license application to FDA for inolimomab for treatment of steroid-refractory acute GvHD in adult patients
The U.S. Food and Drug administration have agreed to start a...
What is the best donor or graft source for patients lacking HLA-matched donors?
A direct comparison of multiple alternative donors and graft sources.
Steroid-refractory GvHD: long term outcomes and risk factors
Simona Pagliuca and colleagues conducted a retrospective study of acute GvHD and chronic GvHD following HSCT to determine the outcomes and...
Editorial theme | Considerations for allo-HSCT from mismatched unrelated donors
A mini review on the current considerations regarding HLA-mismatched related or unrelated donors allo-HSCTs.
Mesenchymal stromal cells
Chemokine receptor antagonists
Fecal microbiota transplant
Nuclear receptor agonists